Cormedix Q2 2024 GAAP EPS $(0.25), Inline, Sales $806.119K Miss $1.674M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cormedix reported its Q2 2024 financial results with a GAAP EPS of $(0.25), which was in line with expectations. However, the company missed its sales estimate, reporting $806.119K compared to the expected $1.674M.
August 14, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cormedix reported a Q2 2024 GAAP EPS of $(0.25), which met expectations, but its sales of $806.119K fell short of the $1.674M estimate.
While the EPS was in line with expectations, the significant miss on sales could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100